Sugi Predict

Sugi Predict / Compounds / SCHEMBL6510845

SCHEMBL6510845

SCHEMBL6510845

COc1ccc(/N=N/c2ccc(CO[C]=O)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.46
▸ IDO1 P14902 3/20 0.46
▸ AGXT P21549 2/20 0.46
▸ MAPT P10636 3/20 0.43
▸ PPARD Q03181 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ APP P05067 3/20 0.41
▸ HTT P42858 1/20 0.41
▸ MIF P14174 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ HDAC1 Q13547 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1456261 1.00 PTGS2 (0.46) PTGS2IDO1AGXTMAPTPPARD
SCHEMBL6341 0.89 IDO1 (0.55) IDO1AGXTAPPHTTNPC1
SCHEMBL29100 0.81 MEN1 (0.45) MAPTPPARDPPARAHTTNPC1
SCHEMBL29101 0.81 MEN1 (0.45) MAPTPPARDPPARAHTTNPC1
SCHEMBL6549408 0.79 MEN1 (0.43) PTGS2MAPTHTTNPC1POLB
SCHEMBL11228126 0.77 PTGS2 (0.53) PTGS2IDO1AGXTMAPTPPARD
SCHEMBL1456264 0.77 PTGS2 (0.46) PTGS2IDO1AGXTMAPTPPARD
SCHEMBL1405603 0.75 CA1 (0.65) PTGS2MAPTNPC1POLBRAB9A
SCHEMBL1405602 0.75 CA1 (0.65) PTGS2MAPTNPC1POLBRAB9A
SCHEMBL16454927 0.74 PTGS2 (0.50) PTGS2IDO1AGXTMAPTPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5120746-A Inhibit gastric acid secretion TOYAMA CHEMICAL CO., LTD. (JP) 1992-06-09 — — US claimed
US-4767863-A Isoxazoline intermediates BRISTOL-MYERS COMPANY (US) 1988-08-30 — — US claimed
US-4643849-A ANTIULCER, ANTISECRETORY AGENTS TOYAMA CHEMICAL CO., LTD. (JP) 1987-02-17 — — US claimed
US-4267340-A BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-05-12 — — US claimed
US-4009159-A PENICILLINS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-02-22 — — US claimed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 — — US claimed
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-06-02 — — US disclosed
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation BAKER BRENDA F (US) 2005-02-17 — — US disclosed
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation ISIS PHARMACEUTICALS, INC. 2005-02-10 — — US disclosed
WO-2004044245-A1 OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed
EP-0644890-B1 OLIGONUCLEOTIDE-POLYAMIDE CONJUGATES HOWARD FLOREY INST OF BR EX PH (AU) 2001-12-05 — — EP disclosed
US-6013434-A Oligonucleotide-polyamide conjugates HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 2000-01-11 — — US disclosed
US-5776948-A BACTERICIDE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1998-07-07 — — US disclosed
US-4094872-A 7-(β-Aminoacylamino)-3-heterocyclic-thiomethyl-3-cephem-4-carboxylic acid derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1978-06-13 — — US disclosed
US-4071527-A Certain benzothiazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1978-01-31 — — US disclosed
US-4036847-A ANTIBACTERIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-07-19 — — US disclosed
US-4009159-A PENICILLINS FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-02-22 — — US disclosed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 — — US disclosed
US-3978063-A 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-08-31 — — US disclosed
US-3963725-A 1,2,3,4-Tetrahydroisoquinoline derivatives and the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050037370-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 PTGS2 3481/4885IDO1 4662/4885AGXT 3279/4885
US-20050118605-A9 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 PTGS2 3481/4885IDO1 4662/4885AGXT 3279/4885
US-20050032069-A1 Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation RNMT, RRBP1, G3BP1 PTGS2 3481/4885IDO1 4662/4885AGXT 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.